Letrozole Teva

Letrozole, the active ingredient in Letrozole Teva, is an aromatase inhibitor presented as a tablet for oral use. It is employed to lower estrogen levels and is indicated for hormone receptor‑positive breast cancer in postmenopausal women and is commonly prescribed in endocrine therapy protocols.

GNH USA supplies Letrozole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company follows stringent quality standards and offers reliable sourcing for oncology treatment regimens across global markets.

Letrozole Teva is an aromatase inhibitor used in the management of estrogen‑driven breast cancer conditions. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen‑driven tumor growth. - Metastatic breast cancer (postmenopausal): Delays disease progression. - Adjuvant therapy for early‑stage breast cancer (postmenopausal): Decreases risk of recurrence.

Common Side Effects: - Hot flashes: Sudden feeling of warmth and sweating. - Joint pain: Discomfort or stiffness in joints. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Queasy sensation often accompanied by an urge to vomit.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, elevated liver enzymes, or hepatic failure. - Bone fracture: Increased risk due to reduced bone mineral density. - Deep vein thrombosis: Swelling, pain, and redness in the leg. - Severe allergic reaction: Rash, swelling, difficulty breathing, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures. - Monitor liver function: Assess hepatic enzymes prior to and during treatment. - Assess bone health: Evaluate bone mineral density and consider calcium/vitamin D supplementation. - Evaluate cardiovascular risk: Watch for signs of thromboembolic events. - Avoid use in pregnancy: Contraindicated (Category X). - Store at ambient temperature below 25°C: Keep in the original pack, protect from moisture.

Letrozole may interact with several medications that affect its metabolism or therapeutic effect. Major Interactions (Avoid): - Concurrent estrogen replacement therapy: May reduce letrozole efficacy. - Strong CYP2A6 inhibitors: Can increase letrozole plasma concentrations. Moderate Interactions (Monitor Closely): - Tamoxifen: Potential antagonistic effect on estrogen pathways. - Warfarin: May alter INR and bleeding risk. - CYP3A4 inducers: May decrease letrozole exposure and effectiveness.